Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 10Recruiting 5Terminated 4Unknown 1Available 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 9Sarcoma 6Endocrine 4NET 3Lymphoid 3Plasma cell 1Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 46Pituitary Neoplasms 19Neoplasms 14Thyroid Neoplasms 13Pheochromocytoma 13Thyroid Carcinoma, Anaplastic 12Thyroid Cancer, Papillary 12Neoplasm Metastasis 12Adrenocortical Carcinoma 11Paraganglioma 9Insulinoma 9Carcinoid Tumor 9Adrenal Gland Neoplasms 9Somatostatinoma 8Glucagonoma 8Colorectal Neoplasms 8Carcinoma, Renal Cell 8Carcinoma, Islet Cell 8Pancreatic Neoplasms 7Gastrinoma 7Carcinoma, Neuroendocrine 7Breast Neoplasms 7Melanoma 6Head and Neck Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Adenoma, Islet Cell 6Small Cell Lung Carcinoma 5Multiple Endocrine Neoplasia Type 1 5Lung Neoplasms 5Gastro-enteropancreatic neuroendocrine tumor 5

Interventions

Everolimus 2trifluridine tipiracil drug combination 1pegfilgrastim 1pasireotide 1dactolisib 1Temozolomide 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Neuroectodermal Tumors, Primitive × Endocrine × Clear all
NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated
18 enrolled
EndocrineNET

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT01374451 2016-12-20

COOPERATE-2

Novartis

Phase 2 Terminated
160 enrolled 17 charts
EndocrineNET

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT00958841 2016-07-26

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Novartis

Phase 2 Terminated
118 enrolled 11 charts
EndocrineGastrointestinal

ACTH Syndrome, Ectopic, Nelson Syndrome, Pancreatic Neoplasms, Pituitary Neoplasms, Neuroectodermal Tumors, Primitive

NCT01628913 2016-04-07

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Novartis

Phase 2 Terminated
62 enrolled 7 charts
EndocrineNET

Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡